Navigation Links
Christine A. Poon Elected to Regeneron Board of Directors
Date:11/15/2010

TARRYTOWN, N.Y., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has elected Christine A. Poon to fill a new seat on its expanded Board of Directors.  Ms. Poon currently serves as dean of Ohio State University's Fisher College of Business.  She was formerly Vice Chairman of the Board of Directors of Johnson & Johnson and Worldwide Chairman of the Johnson & Johnson Pharmaceuticals Group.

"Chris brings an incredibly important commercial perspective and deep strategic and operational knowledge of the pharmaceutical industry to our Board," said P. Roy Vagelos, M.D., Chairman of Regeneron Board of Directors.  "With our pipeline of therapeutic candidates, including several in late-stage clinical trials, we are certain to benefit from Chris' significant experience within the pharmaceutical industry."

"Throughout my career I have enjoyed the thrill of translating basic research ideas into products and services that could make a real difference to global health and wellness," said Chris Poon.  "I am excited to be joining the Regeneron Board to help them achieve their mission of discovering, developing, and commercializing medicines for serious medical conditions."

"Now is an exciting time in Regeneron history as we await the results of several large Phase 3 programs," said Leonard S. Schleifer, M.D., Ph.D. "Chris' vision and leadership helped shape one of the pre-eminent pharmaceutical companies, Johnson & Johnson, and we look forward to her bringing her expertise to our Board."

Ms. Poon became dean of the Fisher College of Business in April 2009.  Prior to joining Ohio State, Ms. Poon had a distinguished career in the pharmaceutical industry.  In her 10 years at Johnson & Johnson, Ms. Poon's responsibilities included managing the pharmaceutical, consumer pharmaceutical, and nutritional businesses, in addition to overseeing the pharmaceutical research pipeline.  Prior to joining Johnson & Johnson, Ms. Poon spent 15 years at Bristol-Myers Squibb, where she held senior leadership positions including president of international medicines and president of medical devices.

Ms. Poon also is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics of Netherlands.  She was named Business Leader of the Future by CNBC/Wall Street Journal in 2005 and consistently has been listed among Forbes' 100 Most Powerful Women in Business.

About RegeneronRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.

Forward Looking StatementThis news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Astellas, the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended September 30, 2010.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7800michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SIRO Clinpharms Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM)
2. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
3. PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades
4. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
5. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
6. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
7. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
8. Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer
9. Greenway Selected by Health Information Exchanges and Regional Physician Groups
10. Patrick J. Zenner Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
11. Award-Winning Thermal Angel Selected as Winner for Outstanding Military Product of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... to their offering. ... latest research Dry eye Drugs Price Analysis and Strategies - 2016, provides ... The research answers the following questions: What ... How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... ... , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be ... Hot,” which will begin airing on February 24, 2017. The show chronicles the weight ... reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC ... converge and explore the world from different perspectives. By providing a place for ... gain understanding, increase empathy, and find greater happiness. , "Our approach to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):